Recurrent aphthous stomatitis – Etiology, serum autoantibodies, anemia, hematinic deficiencies, and management

Chun Pin Chiang, Julia Yu-Fong Chang, Yi Ping Wang, Yu Hsueh Wu, Yang Che Wu, Andy Sun

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Recurrent aphthous stomatitis (RAS) is one of the most common oral mucosal diseases characterized by recurrent and painful ulcerations on the movable or nonkeratinized oral mucosae. Clinically, three types of RAS, namely minor, major, and herpetiform types, can be identified. RAS more commonly affects labial mucosa, buccal mucosa, and tongue. Previous studies indicate that RAS is a multifactorial T cell-mediated immune-dysregulated disease. Factors that modify the immunologic responses in RAS include genetic predisposition, viral and bacterial infections, food allergies, vitamin and microelement deficiencies, systemic diseases, hormonal imbalance, mechanical injuries, and stress. Our previous study found the presence of serum gastric parietal cell antibody, thyroglobulin antibody, and thyroid microsomal antibody in 13.0%, 19.4%, and 19.7% of 355 RAS patients, respectively. We also found anemia, serum iron, vitamin B12, and folic acid deficiencies, and hyperhomocysteinemia in 20.9%, 20.1%, 4.8%, 2.6%, and 7.7% of 273 RAS patients, respectively. Therefore, it is very important to examine the complete blood count, serum autoantibody, hematinic, and homocysteine levels in RAS patients before we start to offer treatments for RAS. Because RAS is an immunologically-mediated disease, topical and systemic corticosteroid therapies are the main treatments of choice for RAS.

Original languageEnglish
JournalJournal of the Formosan Medical Association
DOIs
Publication statusAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Hematinics
Autoantibodies
Anemia
Serum
Mouth Mucosa
Mouth Diseases
Sutton disease 2
Folic Acid Deficiency
Gastric Parietal Cells
Deficiency Diseases
Avitaminosis
Hyperhomocysteinemia
Mechanical Stress
Blood Cell Count
Food Hypersensitivity
Antibodies
Thyroglobulin
Immune System Diseases
Immunologic Factors
Homocysteine

Keywords

  • Gastric parietal cell antibody
  • Hematinic deficiency
  • Recurrent aphthous stomatitis
  • Thyroglobulin antibody
  • Thyroid microsomal antibody

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recurrent aphthous stomatitis – Etiology, serum autoantibodies, anemia, hematinic deficiencies, and management. / Chiang, Chun Pin; Yu-Fong Chang, Julia; Wang, Yi Ping; Wu, Yu Hsueh; Wu, Yang Che; Sun, Andy.

In: Journal of the Formosan Medical Association, 01.01.2018.

Research output: Contribution to journalArticle

@article{82b14939fadc4701b6db14ccfa3807f4,
title = "Recurrent aphthous stomatitis – Etiology, serum autoantibodies, anemia, hematinic deficiencies, and management",
abstract = "Recurrent aphthous stomatitis (RAS) is one of the most common oral mucosal diseases characterized by recurrent and painful ulcerations on the movable or nonkeratinized oral mucosae. Clinically, three types of RAS, namely minor, major, and herpetiform types, can be identified. RAS more commonly affects labial mucosa, buccal mucosa, and tongue. Previous studies indicate that RAS is a multifactorial T cell-mediated immune-dysregulated disease. Factors that modify the immunologic responses in RAS include genetic predisposition, viral and bacterial infections, food allergies, vitamin and microelement deficiencies, systemic diseases, hormonal imbalance, mechanical injuries, and stress. Our previous study found the presence of serum gastric parietal cell antibody, thyroglobulin antibody, and thyroid microsomal antibody in 13.0{\%}, 19.4{\%}, and 19.7{\%} of 355 RAS patients, respectively. We also found anemia, serum iron, vitamin B12, and folic acid deficiencies, and hyperhomocysteinemia in 20.9{\%}, 20.1{\%}, 4.8{\%}, 2.6{\%}, and 7.7{\%} of 273 RAS patients, respectively. Therefore, it is very important to examine the complete blood count, serum autoantibody, hematinic, and homocysteine levels in RAS patients before we start to offer treatments for RAS. Because RAS is an immunologically-mediated disease, topical and systemic corticosteroid therapies are the main treatments of choice for RAS.",
keywords = "Gastric parietal cell antibody, Hematinic deficiency, Recurrent aphthous stomatitis, Thyroglobulin antibody, Thyroid microsomal antibody",
author = "Chiang, {Chun Pin} and {Yu-Fong Chang}, Julia and Wang, {Yi Ping} and Wu, {Yu Hsueh} and Wu, {Yang Che} and Andy Sun",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2018.10.023",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",

}

TY - JOUR

T1 - Recurrent aphthous stomatitis – Etiology, serum autoantibodies, anemia, hematinic deficiencies, and management

AU - Chiang, Chun Pin

AU - Yu-Fong Chang, Julia

AU - Wang, Yi Ping

AU - Wu, Yu Hsueh

AU - Wu, Yang Che

AU - Sun, Andy

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Recurrent aphthous stomatitis (RAS) is one of the most common oral mucosal diseases characterized by recurrent and painful ulcerations on the movable or nonkeratinized oral mucosae. Clinically, three types of RAS, namely minor, major, and herpetiform types, can be identified. RAS more commonly affects labial mucosa, buccal mucosa, and tongue. Previous studies indicate that RAS is a multifactorial T cell-mediated immune-dysregulated disease. Factors that modify the immunologic responses in RAS include genetic predisposition, viral and bacterial infections, food allergies, vitamin and microelement deficiencies, systemic diseases, hormonal imbalance, mechanical injuries, and stress. Our previous study found the presence of serum gastric parietal cell antibody, thyroglobulin antibody, and thyroid microsomal antibody in 13.0%, 19.4%, and 19.7% of 355 RAS patients, respectively. We also found anemia, serum iron, vitamin B12, and folic acid deficiencies, and hyperhomocysteinemia in 20.9%, 20.1%, 4.8%, 2.6%, and 7.7% of 273 RAS patients, respectively. Therefore, it is very important to examine the complete blood count, serum autoantibody, hematinic, and homocysteine levels in RAS patients before we start to offer treatments for RAS. Because RAS is an immunologically-mediated disease, topical and systemic corticosteroid therapies are the main treatments of choice for RAS.

AB - Recurrent aphthous stomatitis (RAS) is one of the most common oral mucosal diseases characterized by recurrent and painful ulcerations on the movable or nonkeratinized oral mucosae. Clinically, three types of RAS, namely minor, major, and herpetiform types, can be identified. RAS more commonly affects labial mucosa, buccal mucosa, and tongue. Previous studies indicate that RAS is a multifactorial T cell-mediated immune-dysregulated disease. Factors that modify the immunologic responses in RAS include genetic predisposition, viral and bacterial infections, food allergies, vitamin and microelement deficiencies, systemic diseases, hormonal imbalance, mechanical injuries, and stress. Our previous study found the presence of serum gastric parietal cell antibody, thyroglobulin antibody, and thyroid microsomal antibody in 13.0%, 19.4%, and 19.7% of 355 RAS patients, respectively. We also found anemia, serum iron, vitamin B12, and folic acid deficiencies, and hyperhomocysteinemia in 20.9%, 20.1%, 4.8%, 2.6%, and 7.7% of 273 RAS patients, respectively. Therefore, it is very important to examine the complete blood count, serum autoantibody, hematinic, and homocysteine levels in RAS patients before we start to offer treatments for RAS. Because RAS is an immunologically-mediated disease, topical and systemic corticosteroid therapies are the main treatments of choice for RAS.

KW - Gastric parietal cell antibody

KW - Hematinic deficiency

KW - Recurrent aphthous stomatitis

KW - Thyroglobulin antibody

KW - Thyroid microsomal antibody

UR - http://www.scopus.com/inward/record.url?scp=85056472997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056472997&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2018.10.023

DO - 10.1016/j.jfma.2018.10.023

M3 - Article

AN - SCOPUS:85056472997

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -